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and hypercoagulability during emergency
department evaluation for acute
coronary syndromePosttraumatic stress disorder is associated with risk for incident
and recurrent cardiovascular disease (CVD) and mortality, but the
mechanisms for the association are unclear [4]. Recent studies
have shown that PTSD is associated with greater coronary artery
calcium [1], reduced coronary blood ﬂow [8], and autonomic imbal-
ance [8].
Thrombus formation is critical in the pathogenesis of coronary artery
disease, and faster clotting speed as measured by activated partial
thromboplastin time (aPTT) has been associated with recurrent cardio-
vascular events in acute coronary syndrome (ACS) patients [2]. Only
two small studies have investigated the association of PTSD with
markers of coagulation. One case–control study (N = 14 PTSD)
suggested a linear association of PTSD symptoms with clotting factors
VII, VIII, XII, ﬁbrinogen, and D-dimer [9]. Another study found increased
levels of vWF antigen and factor VIII in 30 patients with severe chronic
PTSD [6].
In order to determine whether PTSD symptoms are associated with
hypercoagulability, a mechanism underlying ACS onset, we tested the
association of PTSD symptoms from a prior traumatic event with
clotting parameters in 99 patients who presented with an ACS event.
The Reactions to Acute Care in Hospitalization (REACH) study is an
ongoing observational cohort study of psychosocial factors and
cardiac/mortality risk in cardiac patients being evaluated for ACS. Partic-
ipants, who later had ACS diagnosis conﬁrmed, underwent testing for
aPTT, prothrombin time (PT), and platelet count as part of a cardiac
evaluation in the ED. Either during inpatient stay or by telephone a
median of 3 days later, participants completed the Life Events Checklist
[5] for prior traumatic event burden and the PTSD Checklist-Civilian
version (PCL) with reference to the most stressful prior traumatic
event. The PCL provides a continuous measure of PTSD symptom
severity over 17 items with high diagnostic utility – a cutoff score of
50 is 82% sensitive, 83% speciﬁc for PTSD diagnosis via Structured
Clinical Interview for DSM disorders [10]. Age, sex, ACS type [Non-ST
elevation myocardial infarction (NSTEMI) or unstable angina (UA)],
daily aspirin or anticoagulant history, ED aspirin, heparin, or warfarin
receipt, Global Registry of Acute Coronary Events (GRACE) score, and
Charlson comorbidity index were taken from chart review. Covariates
were chosen a priori for variates known to inﬂuence aPTT. All
participants provided informed consent, and the research was carried
out in accordance with the Declaration of Helsinki.
Three linear regression models were tested to determine whether
PCL-C scores (log transformed)were associatedwithhypercoagulabilityhttp://dx.doi.org/10.1016/j.ijcme.2016.03.002
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above. We tested for collinearity using the variance inﬂation factor, no
signiﬁcant collinearity was found.
In 99 participants (Table 1), the cumulative traumatic event burden
was 3.3 ± 2.9 events, with a mean PCL score of 27 ± 12 (22% screened
positive for pre-existing PTSD at a cutoff of 35). Themost common trau-
ma inducing event was the sudden, unexpected death of a close loved
one (37%). aPTT and PT in the sample were 30.4 ± 8.3 and 14.4 ±
3.0 s, respectively. In the fully adjusted model, higher PTSD symptoms
were associated with lower aPTT values (β=−0.22, p = .03); which
corresponds to 1.5 s of aPTT per 10 points on the PCL. No other variable
was statistically signiﬁcant, but history of anticoagulant use (β= 0.17,
p = .09), GRACE score (β= 0.26, p = .09) and heparin receipt in the
ED (β= 0.19, p = .06) were marginally associated with greater aPTT.
The full model explained 13% of the variability in aPTT [F(11,87) =
2.30, p = .02; R2adj = .13]. PTSD symptoms were not signiﬁcantly
associated with PT values (β = −0.06, p = .41) or platelet count
(β=−0.01, p = .98). (See Table 2.)
We examined whether PTSD symptoms were associated with
hypercoagulability in a cohort of ACS patients during ED evaluation.
Although PTSD can occur due to an ACS event, we screened for PTSD
symptoms in relation to a traumatic event prior to arriving to the ED.
We found that PTSD symptoms may be associated with reduced aPTT,
but not PT or platelet count. The aPTT reﬂects the activity of the intrinsic
and common coagulation pathways, including Factor VIII, IX, X, XI, and
XII. Conversely, PT assesses the activity of the extrinsic pathway,
particularly Factor VII, a Vitamin K-dependent procoagulant with a
short half-life [7]. Therefore, our study suggests that PTSD symptoms
may be associatedwith activation of the intrinsic and common coagula-
tion pathways.
Previously, Von Kanel et al. found that increased levels of ﬁbrinogen
and Factor VIII in patients with PTSD, suggesting subthreshold changes
in coagulation [9]. Our ﬁndings suggest a detectable change in aPTT
during an acutely stressful experience, such as undergoing evaluation
for a cardiac event in the ED. As such, patients with PTSD may exhibit
a baseline level of subthreshold hypercoagulability, which becomes
signiﬁcant in the setting of subsequent acute stress.
Arbab-Zadeh et al. proposed a “perfect storm” model for under-
standing the pathophysiology of acute coronary syndrome, wherein a
multitude of biological events coalesce to precipitate ACS [3]. When
applied to the relationship between PTSD and CVD, the “perfect
storm”model captures the complexity of the physiological, psychiatric,
and psychosocial factors that play a role in conferring disease. Our
analysis suggests that hypercoagulability may be part of the constella-
tion of processes that predispose PTSD patients to ACS onset.
A limitation of this observational cohort study is that aPTT represents
the collective behavior of multiple coagulation factors, so the relative in-
ﬂuence of individual coagulant proteins in fostering hypercoagulability
cannot be determined. However, our ﬁndings provide preliminary evi-
dence that the cardiovascular effects of PTSD may be partially explained
by hypercoagulability. Additional research using more detailed analysis
of clotting factors in large populations can further our understanding ofe under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Participant characteristics.
Mean ± SD or % of sample
Age 61 ± 12
Male sex 65%
Non-ST elevation MI 38%
History of daily aspirin use 63%
History of anticoagulant usea 7%
Aspirin in ED prior to aPTT 47%
Heparin in ED prior to aPTT 3%
GRACE score b 91 ± 28
Charlson comorbidity indexc 1.9 ± 1.9
Lifetime traumatic events 3.3 ± 2.9
PCL-C scored 27 ± 12
aPTTe 30.4 ± 8.3
PT 14.4 ± 3.0
Platelet count 228 ± 60
a Warfarin or heparin use within 7 days prior to presentation.
b Global Registry of Acute Coronary Events score. Higher scores represent greater
6-month risk (e.g., 100–127 predicts a 4.5–11% 6-month mortality risk).
c Number of comorbidities weighted by associated mortality risk (b2 predicts
b10% risk of 10-year mortality).
d PTSD Checklist-Civilian.
e Activated partial thromboplastin time.
Table 2
Multiple regression predicting activated partial thromboplastin time (aPTT) from PTSD
symptom score, and demographic and clinical covariates.
Variable B SE (B) β p
Age −.01 .10 −.02 .91
Sex .32 1.69 .02 .85
NSTEMI 2.53 1.68 .15 .14
GRACE cardiac risk score .08 .05 .26 .09
Charlson Comorbidity score .48 .49 .11 .33
Cumulative traumatic events .30 .29 .11 .29
PCL-C PTSD symptoms (log transformed) −4.82 2.23 −.22 .03
Daily aspirin history −2.07 1.77 −.12 .25
Anticoagulant history 5.39 3.16 .17 .09
Aspirin in ED 1.37 1.60 .08 .39
Heparin in ED 8.97 4.68 .19 .06
2 V.T. Ho et al. / IJC Metabolic & Endocrine 11 (2016) 1–2the link between PTSD and cardiovascular risk. Further, serial testing of
coagulation parameters may better characterize the extent and
magnitude of hypercoagulability in PTSD patients over time.
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